Volume 3 Supplement 1

Abstracts of the Breast Cancer Immunotherapy Symposium (BRECIS): Sidra Symposia Series

Open Access

CTLA-4 checkpoint blockade in breast cancer, a case in point report

  • Chiara Dellepiane1,
  • Michela Lia2 and
  • Mario Roberto Sertoli1
Journal for ImmunoTherapy of Cancer20153(Suppl 1):O4

https://doi.org/10.1186/2051-1426-3-S1-O4

Published: 14 August 2015

A patient concomitantly affected by breast cancer and melanoma is presented in order to contribute to the ongoing debate on breast cancer immunotherapy [1, 2]. In 1996 the patient was operated on for left early breast cancer and treated with adjuvant radiotherapy and 5 years Tamoxifen. In 2009 biochemical progression and bone metastases appeared so Letrozole hormonal therapy was carried out, ensuing in clinical stabilization. In 2010, a left arm cutaneous melanoma was excised (pT4a Breslow 4.5 mm), and axillary nodal dissection detecting an involved node. Because of subsequent in-transit metastases, the patient underwent chemo-hyperthermic perfusion, reaching a dermic complete response (CR). Suddenly melanoma progressed in the lung and liver, as confirmed by ultrasound driven biopsy. Chemotherapy (DTIC) was given, achieving visceral partial response. At this point Ipilimumab [3] was available and CR of liver, lung, and dermic metastases was obtained after 4 cycles, while bone lesions remained stable and considered breast cancer. Four months later novel liver metastases appeared and biopsy unexpectedly confirmed their breast cancer origin. The patient after unsuccessful chemotherapy, finally died of liver failure, without evidence of melanoma metastases. This very special case shows the impressive discrepancy in response to CTLA4 check-point therapy between melanoma and breast cancer.

Authors’ Affiliations

(1)
Clinic of Medical Oncology, IRCCS SAN MARTINO IST, Genoa University
(2)
EORTC

References

  1. Emens LA: LA Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther. 2012, 12 (12): 1597-611. 10.1586/era.12.147. doi: 10.1586/era.12.147. ReviewPubMed CentralView ArticlePubMedGoogle Scholar
  2. Nanda R, Chow LQ, Dees EC, et al: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. SABCS 2014. 2014, San Antonio, Texas, 10.1158/1538-7445.SABCS14-S1-09. Abstract S1-09Google Scholar
  3. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010, 363: 711-723. 10.1056/NEJMoa1003466.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Dellepiane et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement